Review



human c5a elisa kit  (Hycult Biotech)


Bioz Verified Symbol Hycult Biotech is a verified supplier
Bioz Manufacturer Symbol Hycult Biotech manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Hycult Biotech human c5a elisa kit
    Human C5a Elisa Kit, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human c5a elisa kit/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    human c5a elisa kit - by Bioz Stars, 2025-02
    94/100 stars

    Images



    Similar Products

    94
    Hycult Biotech human c5a elisa kit
    Human C5a Elisa Kit, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human c5a elisa kit/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    human c5a elisa kit - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech c5a
    Serum concentrations of C3a and <t>C5a</t> in FD patients. (A) C3a and (B) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18) and treatment-naiüve (n=24) FD patients. (C) C3a and (D) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18), treatment-naiüve FD patients and from the same patients under ERT (n=17). Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by Mann-Whitney test (A, B) when data were not normally distributed or Ordinary one-way ANOVA with Tukey’s posthoc test (C, D) in case of normal distribution. Data in A, B are shown as median and range with 25th and 75th percentile. Data in (C, D) are shown as mean + SEM (C, D) . *p<0.05, **p<0.01; ***p<0.001; ****p<0.0001. (E, F) Percentage of serum samples from healthy controls (white bar, n=18), treatment-naiüve FD patients (black bar, n=17) and from the same patients under ERT (grey bar, n=17) with levels of (E) ≤5,000 ng/ml or >5,000 ng/ml of C3a or (F) ≤20 ng/ml, 21-35 ng/ml or >35 ng/ml C5a in serum. (G, H) Linear regression analysis of C5a and C3a serum levels (ng/ml) in FD patients before (G) and after (H) ERT (n=17). R 2 is the coefficient of determination of linear regression and ranges from 0 (no linear regression) to 1 (perfect linear regression).
    C5a, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c5a/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    c5a - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech c5a, human, elisa kit
    Serum concentrations of C3a and <t>C5a</t> in FD patients. (A) C3a and (B) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18) and treatment-naiüve (n=24) FD patients. (C) C3a and (D) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18), treatment-naiüve FD patients and from the same patients under ERT (n=17). Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by Mann-Whitney test (A, B) when data were not normally distributed or Ordinary one-way ANOVA with Tukey’s posthoc test (C, D) in case of normal distribution. Data in A, B are shown as median and range with 25th and 75th percentile. Data in (C, D) are shown as mean + SEM (C, D) . *p<0.05, **p<0.01; ***p<0.001; ****p<0.0001. (E, F) Percentage of serum samples from healthy controls (white bar, n=18), treatment-naiüve FD patients (black bar, n=17) and from the same patients under ERT (grey bar, n=17) with levels of (E) ≤5,000 ng/ml or >5,000 ng/ml of C3a or (F) ≤20 ng/ml, 21-35 ng/ml or >35 ng/ml C5a in serum. (G, H) Linear regression analysis of C5a and C3a serum levels (ng/ml) in FD patients before (G) and after (H) ERT (n=17). R 2 is the coefficient of determination of linear regression and ranges from 0 (no linear regression) to 1 (perfect linear regression).
    C5a, Human, Elisa Kit, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c5a, human, elisa kit/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    c5a, human, elisa kit - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech c5a elisa kit
    Serum concentrations of C3a and <t>C5a</t> in FD patients. (A) C3a and (B) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18) and treatment-naiüve (n=24) FD patients. (C) C3a and (D) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18), treatment-naiüve FD patients and from the same patients under ERT (n=17). Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by Mann-Whitney test (A, B) when data were not normally distributed or Ordinary one-way ANOVA with Tukey’s posthoc test (C, D) in case of normal distribution. Data in A, B are shown as median and range with 25th and 75th percentile. Data in (C, D) are shown as mean + SEM (C, D) . *p<0.05, **p<0.01; ***p<0.001; ****p<0.0001. (E, F) Percentage of serum samples from healthy controls (white bar, n=18), treatment-naiüve FD patients (black bar, n=17) and from the same patients under ERT (grey bar, n=17) with levels of (E) ≤5,000 ng/ml or >5,000 ng/ml of C3a or (F) ≤20 ng/ml, 21-35 ng/ml or >35 ng/ml C5a in serum. (G, H) Linear regression analysis of C5a and C3a serum levels (ng/ml) in FD patients before (G) and after (H) ERT (n=17). R 2 is the coefficient of determination of linear regression and ranges from 0 (no linear regression) to 1 (perfect linear regression).
    C5a Elisa Kit, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c5a elisa kit/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    c5a elisa kit - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech hk349 elisa kit
    Serum concentrations of C3a and <t>C5a</t> in FD patients. (A) C3a and (B) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18) and treatment-naiüve (n=24) FD patients. (C) C3a and (D) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18), treatment-naiüve FD patients and from the same patients under ERT (n=17). Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by Mann-Whitney test (A, B) when data were not normally distributed or Ordinary one-way ANOVA with Tukey’s posthoc test (C, D) in case of normal distribution. Data in A, B are shown as median and range with 25th and 75th percentile. Data in (C, D) are shown as mean + SEM (C, D) . *p<0.05, **p<0.01; ***p<0.001; ****p<0.0001. (E, F) Percentage of serum samples from healthy controls (white bar, n=18), treatment-naiüve FD patients (black bar, n=17) and from the same patients under ERT (grey bar, n=17) with levels of (E) ≤5,000 ng/ml or >5,000 ng/ml of C3a or (F) ≤20 ng/ml, 21-35 ng/ml or >35 ng/ml C5a in serum. (G, H) Linear regression analysis of C5a and C3a serum levels (ng/ml) in FD patients before (G) and after (H) ERT (n=17). R 2 is the coefficient of determination of linear regression and ranges from 0 (no linear regression) to 1 (perfect linear regression).
    Hk349 Elisa Kit, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hk349 elisa kit/product/Hycult Biotech
    Average 94 stars, based on 1 article reviews
    hk349 elisa kit - by Bioz Stars, 2025-02
    94/100 stars
      Buy from Supplier

    Image Search Results


    Serum concentrations of C3a and C5a in FD patients. (A) C3a and (B) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18) and treatment-naiüve (n=24) FD patients. (C) C3a and (D) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18), treatment-naiüve FD patients and from the same patients under ERT (n=17). Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by Mann-Whitney test (A, B) when data were not normally distributed or Ordinary one-way ANOVA with Tukey’s posthoc test (C, D) in case of normal distribution. Data in A, B are shown as median and range with 25th and 75th percentile. Data in (C, D) are shown as mean + SEM (C, D) . *p<0.05, **p<0.01; ***p<0.001; ****p<0.0001. (E, F) Percentage of serum samples from healthy controls (white bar, n=18), treatment-naiüve FD patients (black bar, n=17) and from the same patients under ERT (grey bar, n=17) with levels of (E) ≤5,000 ng/ml or >5,000 ng/ml of C3a or (F) ≤20 ng/ml, 21-35 ng/ml or >35 ng/ml C5a in serum. (G, H) Linear regression analysis of C5a and C3a serum levels (ng/ml) in FD patients before (G) and after (H) ERT (n=17). R 2 is the coefficient of determination of linear regression and ranges from 0 (no linear regression) to 1 (perfect linear regression).

    Journal: Frontiers in Immunology

    Article Title: Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy

    doi: 10.3389/fimmu.2024.1307558

    Figure Lengend Snippet: Serum concentrations of C3a and C5a in FD patients. (A) C3a and (B) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18) and treatment-naiüve (n=24) FD patients. (C) C3a and (D) C5a concentrations (ng/ml) in serum samples from healthy controls (n=18), treatment-naiüve FD patients and from the same patients under ERT (n=17). Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by Mann-Whitney test (A, B) when data were not normally distributed or Ordinary one-way ANOVA with Tukey’s posthoc test (C, D) in case of normal distribution. Data in A, B are shown as median and range with 25th and 75th percentile. Data in (C, D) are shown as mean + SEM (C, D) . *p<0.05, **p<0.01; ***p<0.001; ****p<0.0001. (E, F) Percentage of serum samples from healthy controls (white bar, n=18), treatment-naiüve FD patients (black bar, n=17) and from the same patients under ERT (grey bar, n=17) with levels of (E) ≤5,000 ng/ml or >5,000 ng/ml of C3a or (F) ≤20 ng/ml, 21-35 ng/ml or >35 ng/ml C5a in serum. (G, H) Linear regression analysis of C5a and C3a serum levels (ng/ml) in FD patients before (G) and after (H) ERT (n=17). R 2 is the coefficient of determination of linear regression and ranges from 0 (no linear regression) to 1 (perfect linear regression).

    Article Snippet: For quantification of complement cleavage products C3a/C3a-desArg (C3a) as well as C5a/C5a-desArg (C5a) in serum, commercial C3a (HK354, Hycult Biotech, Uden, Netherlands) and C5a (HK349, Hycult Biotech, Uden, Netherlands) human enzyme-linked immunosorbent assay (ELISA) kits were used according to the manufacturer’s instructions.

    Techniques: MANN-WHITNEY

    C3a, C5a and lyso-Gb3 concentrations in the circulation of FD patients with missense/nonsense mutations. (A–D) C3a, (E–H) C5a and (I–L) lyso-Gb3 concentrations (ng/ml) in samples from (A, E, I) treatment-naiüve (n=17), (B, F, J) FD patients under ERT (n=17) with missense (n=9) or nonsense (n=8) GLA mutations and from FD patients with (C, G, K) missense (n=9) or (D, H, L) nonsense (n=8) GLA mutations before (V0) or under ERT (V1). Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by unpaired t-test (A, B, E, F, I, J ) or paired t- test (C, D, G, H, K, L) . Data in (A, B, E, F, I, J) are shown as mean + SEM. *p<0.05; ***p<0.001.

    Journal: Frontiers in Immunology

    Article Title: Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy

    doi: 10.3389/fimmu.2024.1307558

    Figure Lengend Snippet: C3a, C5a and lyso-Gb3 concentrations in the circulation of FD patients with missense/nonsense mutations. (A–D) C3a, (E–H) C5a and (I–L) lyso-Gb3 concentrations (ng/ml) in samples from (A, E, I) treatment-naiüve (n=17), (B, F, J) FD patients under ERT (n=17) with missense (n=9) or nonsense (n=8) GLA mutations and from FD patients with (C, G, K) missense (n=9) or (D, H, L) nonsense (n=8) GLA mutations before (V0) or under ERT (V1). Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by unpaired t-test (A, B, E, F, I, J ) or paired t- test (C, D, G, H, K, L) . Data in (A, B, E, F, I, J) are shown as mean + SEM. *p<0.05; ***p<0.001.

    Article Snippet: For quantification of complement cleavage products C3a/C3a-desArg (C3a) as well as C5a/C5a-desArg (C5a) in serum, commercial C3a (HK354, Hycult Biotech, Uden, Netherlands) and C5a (HK349, Hycult Biotech, Uden, Netherlands) human enzyme-linked immunosorbent assay (ELISA) kits were used according to the manufacturer’s instructions.

    Techniques:

    C3a, C5a and lyso-Gb3 concentrations in the circulation of FD patients with ADA-negative/positive status. (A–D) C3a, (E–H) C5a and (I–L) lyso-Gb3 concentrations (ng/ml) in serum from ADA-negative (n=6) or ADA-positive (n=11) (A, E, I) patients, who were either treatment-naiüve (n=17) or (B, F, J) received ERT (n=17). (C, G, K) ADA-negative (n=6) or (D, H, L) ADA-positive (n=11) FD patients before (V0) or under ERT (V1). Red lines denote patients with missense mutations. Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by unpaired t-test (A, B, E, F, I, J) or paired t-test (C, D, G, H, K, L) . Data in (A, B, E, F, I, J) are shown as mean + SEM. *p<0.05; ***p<0.001.

    Journal: Frontiers in Immunology

    Article Title: Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy

    doi: 10.3389/fimmu.2024.1307558

    Figure Lengend Snippet: C3a, C5a and lyso-Gb3 concentrations in the circulation of FD patients with ADA-negative/positive status. (A–D) C3a, (E–H) C5a and (I–L) lyso-Gb3 concentrations (ng/ml) in serum from ADA-negative (n=6) or ADA-positive (n=11) (A, E, I) patients, who were either treatment-naiüve (n=17) or (B, F, J) received ERT (n=17). (C, G, K) ADA-negative (n=6) or (D, H, L) ADA-positive (n=11) FD patients before (V0) or under ERT (V1). Red lines denote patients with missense mutations. Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by unpaired t-test (A, B, E, F, I, J) or paired t-test (C, D, G, H, K, L) . Data in (A, B, E, F, I, J) are shown as mean + SEM. *p<0.05; ***p<0.001.

    Article Snippet: For quantification of complement cleavage products C3a/C3a-desArg (C3a) as well as C5a/C5a-desArg (C5a) in serum, commercial C3a (HK354, Hycult Biotech, Uden, Netherlands) and C5a (HK349, Hycult Biotech, Uden, Netherlands) human enzyme-linked immunosorbent assay (ELISA) kits were used according to the manufacturer’s instructions.

    Techniques: